Welcome to our dedicated page for Splash Beverage Group news (Ticker: SBEV), a resource for investors and traders seeking the latest updates and insights on Splash Beverage Group stock.
Splash Beverage Group, Inc. reports developments for a portfolio of alcoholic and non-alcoholic beverage brands. Its recurring updates cover brand distribution for Pulpoloco sangria, SALT flavored tequilas, Copa di Vino wine by the glass, and hydration or recovery drinks, including retail authorizations and state-level alcohol-market access.
Company news also includes operating and financial results calls, capital-structure updates, private-placement activity, material agreements, shareholder voting matters, and governance changes. These items reflect Splash Beverage Group's model of managing and expanding consumer beverage brands through retail channels, distribution relationships, and public-company financing activity.
Endovia Health Sciences (NYSE American: EDVA), formerly Splash Beverage (SBEV), announced that the FDA Center for Veterinary Medicine has established Investigational New Animal Drug (INAD) File No. 14145 for its CannEpil® veterinary development program. This is the first regulatory milestone under Endovia Health’s collaboration with Lupvindol Biosciences and formally begins FDA regulatory engagement for CannEpil as an investigational veterinary pharmaceutical.
Endovia Health is initially targeting cancer‑related pain in canine oncology and plans to pursue the FDA’s Minor Use / Minor Species (MUMS) designation and Conditional Approval pathway. According to the company, Splash holds exclusive global rights to develop and commercialize CannEpil, and the business has rebranded to reflect a diversified cannabinoid‑based health sciences platform.
Splash Beverage Group (NYSE American: SBEV) will change its corporate name to Endovia Health Sciences and begin trading on the NYSE American under the new ticker “EDVA” effective at market open on Monday, August 24, 2026. The company said the new identity reflects its strategic transformation from legacy beverage operations into a diversified cannabinoid-based health sciences platform focused on three areas: commercial pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and cannabinoid-based consumer wellness and beverage products.
According to the company, it recently advanced its CannEpil® veterinary program by opening an Investigational New Animal Drug (INAD) file with the FDA’s Center for Veterinary Medicine. The name and ticker change will not affect shareholder rights, and existing stock certificates will remain valid with no required shareholder action.
Splash Beverage (NYSE American: SBEV) reported that loss from continuing operations for the six months ended June 30, 2026 was about $4 million, versus about $11 million a year earlier, an improvement of roughly $7 million or 64%, which management attributes mainly to cost-reduction initiatives tied to exiting alcoholic beverages and pivoting to cannabinoid health and wellness.
According to the company, key steps included cutting corporate overhead, simplifying legacy obligations and advancing a strategic repositioning toward pharmaceutical, veterinary and cannabinoid health sciences. After quarter-end, Splash entered an exclusive global license for CannEpil, expanded that license into veterinary indications, signed a development and collaboration agreement with Lupvindol Biosciences for FDA-regulated veterinary products, began preparations to relaunch CannEpil in select international markets, and announced a planned rebrand to Endovia Health Sciences with a new ticker expected to be effective on August 24, 2026.
Splash Beverage Group (NYSE American: SBEV) plans to change its corporate name to Endovia Health Sciences and its ticker to EDVA, effective August 21, 2026, alongside launching EndoviaSciences.com. The rebrand reflects a strategic shift from a legacy beverage business to a diversified cannabinoid health sciences platform.
The company outlines three growth pillars: commercial pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and consumer cannabinoid wellness and beverage products. According to management, recent actions include acquiring differentiated pharmaceutical IP, establishing international commercialization opportunities, and building an experienced cannabinoid pharmaceutical development team to support its long-term vision and mission.
Splash Beverage Group (NYSE American: SBEV) entered a strategic development and collaboration agreement with Lupvindol Biosciences to advance CannEpil as a potential FDA-regulated veterinary pharmaceutical for companion-animal oncology and chronic pain, initially focusing on canine applications through the FDA Center for Veterinary Medicine’s INAD and potential Conditional Approval pathway.
Lupvindol will lead scientific, product-development and regulatory activities, while Splash provides milestone-based funding, leads commercialization and capital-markets strategy, and will own the medical technology, study data, regulatory submissions and foreground IP, retaining future licensing and commercialization control. The agreement aligns payments with defined regulatory milestones; Lupvindol will cover FDA sponsor fees through Conditional Approval, and Splash will fund any FDA-required pilot study subject to a contractual cap. Splash licenses CannEpil from Argent Biopharma and is repositioning itself as a diversified cannabinoid health, wellness and biopharmaceutical platform. CannEpil is not FDA-approved for veterinary use, and there is no assurance of approval.
Splash Beverage Group (NYSE American: SBEV) expanded its exclusive global CannEpil® license to cover veterinary therapeutics, creating a second FDA-regulated pharmaceutical development platform alongside its existing human program. The amendment grants exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions, with Splash paying Argent BioPharma a 10% royalty on net revenues from veterinary uses.
CannEpil is a pharmaceutical-grade CBD/THC oral solution manufactured under EU-GMP standards, originally developed for drug-resistant epilepsy and already holding an FDA IND for human development. Splash initially plans to pursue companion-animal oncology and chronic pain indications, focusing on canine applications, via FDA Center for Veterinary Medicine INAD and Conditional Approval pathways. The company is also finalizing a strategic joint venture with an established cannabinoid pharmaceutical partner to lead veterinary development, aligning this move with its broader strategy to build a diversified cannabinoid health sciences platform.
Splash Beverage Group (NYSE American: SBEV) announced two major steps to advance its NYSE American compliance plan and strengthen its balance sheet. The company settled approximately $3.3 million of legacy accounts payable and accrued liabilities for about $550,000 in cash, expecting an approximate $2.75 million gain from extinguishment of indebtedness, subject to final accounting review. The settlements are expected to remove roughly 84% of the negotiated obligations while paying about 17% of their face value.
The board also approved a 1-for-4 reverse stock split of common shares. Outstanding shares will be reduced from about 25.2 million to 6.3 million, and authorized shares from 400 million to 100 million. No fractional shares will be issued; fractions will be rounded down to the nearest whole share. The split becomes effective after market close on July 24, 2026, with post-split trading starting July 27, 2026 under the symbol SBEV with new CUSIP 84862C401. According to Splash Beverage, the reverse split is intended to help maintain compliance with NYSE American minimum share price requirements.
Splash Beverage Group (NYSE American:SBEV) announced that NYSE American has accepted its plan to regain compliance with continued listing standards and granted a compliance period through January 29, 2027.
The approval allows continued trading while Splash advances its transition into a cannabinoid wellness and pharmaceutical platform, supported by an equity line facility, a strategic investment in Avicanna, and exclusive worldwide licensing rights to CannEpil®.
Splash Beverage Group (NYSE American: SBEV) signed an exclusive global licensing deal with Argent BioPharma for CannEpil, a patent-protected cannabinoid therapy for drug-resistant epilepsy with existing access in Ireland, the UK, Germany and Australia.
The 20-year license includes worldwide commercialization rights, a $1 million strategic investment, preferred equity issuance and a 15% royalty on net revenue.
Splash Beverage Group (NYSE American: SBEV) signed an exclusive global licensing deal with Argent BioPharma for CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy. CannEpil has established patient access in several European markets and an FDA Investigational New Drug number for future U.S. development.
The agreement grants Splash worldwide rights for at least 20 years, including sublicensing and next-generation products. Financing includes a $1 million strategic investment, ~$5 million debt forgiveness for Argent, $5.5 million in new Splash preferred equity, and a 15% net revenue royalty to Argent.